Box Seg

G-10 Inc.

P.O. Box 223662 Chantilly, VA 20154 Ph. (703) 542-5588 Cell (703) 725-9876 NOV 0 6 2006

Date: November 1, 2006

Dr. Ronald Schwadron, Ph.D Art unit 1644 Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313, 1450

Re: Application No 09/474 677 D

Applicant: Yash Sharma

Dear Dr. Schwadron:

This has reference to my interview with you on October 18, 2006 in your office regarding sequence listing. Thanks for your advice and help. Please find the enclosed corrected sequence listing, and also the NIH web page listing Lukor as anti-HIV compound and USDA table listing NGNA as component of common food items. Also included in this package is our human clinical trials using NGNA derived from common food item Sea cucumber and related references.

These documents provide sufficient evidence of enablement and further proof of NGNA as potential natural anti – HIV compound.

In view of these evidences, the application is in good condition for allowance.

Respectfully submitted.

Yash Sharma, Ph.D

43393 Cedar Pond Place

CHANTILLY VA 20152



Notice to Comply

Application No	Applicant(s)	
09/474677	Sharma	
Examiner	Art Unit	
Ron Schwadron,	1644	
Ph.D.		

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e)
☐ 7. Other:
Applicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application.
☑ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
PI EASE DETURN A CORV OF THE NAME OF THE PARTY.

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY